Willingness to switch to long-acting regimens among people with HIV: a systematic review and meta-analysis.
Kyra F Mendes de Leon, Roos D Klungers, Pythia T Nieuwkerk et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis assessed the willingness of adults with HIV to switch from daily oral antiretroviral therapy to long-acting regimens (LAR). The analysis included 22 studies, revealing that 70% of participants were willing to switch to any LAR, with two-monthly intramuscular injections showing a willingness of 60%.
Key findings
- 70% of adults with HIV were willing to switch to any long-acting regimen.
- Willingness to switch to two-monthly intramuscular injections was 60%.
- The majority of studies were conducted in Europe or North America (96%).
- Limited research exists on alternative long-acting regimens.
Why it matters
Understanding patient preferences for long-acting regimens is crucial for informing treatment policies and improving adherence to HIV management. This knowledge can enhance patient autonomy and convenience in care.
What to keep in mind
Limited studies investigated willingness for alternative long-acting regimens, and low and middle-income countries were underrepresented.